Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Haas

Showing results (501-510 of 554) with videos related to

Pageof 56
Sort By:
British Journal of Cancer|October 16, 2018
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumoursAmit Maity, Rosemarie Mick, Alexander C Huang, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2006
MelanomaAlan N Houghton, Daniel G Coit, Adil Daud, et al.
Reviews in Fish Biology and Fisheries|June 7, 2021
Food for all: designing sustainable and secure future seafood systemsA K Farmery, K Alexander, K Anderson, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Prostate Cancer and Prostatic Diseases|October 3, 2020
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamideNaomi B Haas, Michael J LaRiviere, Thomas H Buckingham, et al.
Pageof 56

Showing results (501-510 of 554) with videos related to

Sort By:
Pageof 56
British Journal of Cancer|October 16, 2018
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumoursAmit Maity, Rosemarie Mick, Alexander C Huang, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2006
MelanomaAlan N Houghton, Daniel G Coit, Adil Daud, et al.
Reviews in Fish Biology and Fisheries|June 7, 2021
Food for all: designing sustainable and secure future seafood systemsA K Farmery, K Alexander, K Anderson, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Prostate Cancer and Prostatic Diseases|October 3, 2020
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamideNaomi B Haas, Michael J LaRiviere, Thomas H Buckingham, et al.
Pageof 56